A Phase 2/3 interventional study of BCX4161 and Placebo in Hereditary Angioedema and HAE, sponsored by BioCryst Pharmaceuticals. Completed at 40 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by BioCryst Pharmaceuticals · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals — 2 open to participants now, 5 under way, 4 of them phase 3. Angioedemas, Hereditary · BioCryst Pharmaceuticals.
Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, this one is the 7th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2014, is one of 2 in phase 2/3, and was the 4th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →2 of the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Astria Therapeutics, Inc. · Sites in United States, Brazil, Bulgaria and 15 more countries
Ages 12+
BioCryst Pharmaceuticals · Sites in Canada, Czechia, France and 8 more countries
Ages 2+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 9
First in 2013; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 54 across the 21 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
BioCryst Pharmaceuticals is the lead sponsor of 54 studies on the registry; 1 is open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
1 of the studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06842823Phase 3Astria Therapeutics, Inc.A Study of Navenibart in Participants With Hereditary Angioedema | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of an oral treatment, BCX4161, in preventing acute attacks in participants with hereditary angioedema (HAE). Eligible participants will be randomized to receive one of two doses of BCX4161 or placebo for 12 weeks. The study will compare the number of acute attacks in each treatment group, as well as a number of other clinical outcomes, and the safety and tolerability of each dose of BCX4161 compared to placebo.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three BCX4161 capsules (100 mg) and two placebo capsules to be taken three times daily by mouth
Drug: BCX4161 · Drug: Placebo
Five BCX4161 capsules (100 mg) to be taken three times daily by mouth
Drug: BCX4161
Five placebo capsules to be taken three times daily by mouth
Drug: Placebo
The Mean Acute Angioedema Attack Rate
An angioedema attack was defined as swelling at any location reported by participant, which had no swelling earlier. Total number of confirmed attacks during the treatment period standardized to a weekly attack-rate to adjust for the total duration of treatment. The attack rate was derived for each participant by treatment period. The weekly attack rate was equal to the total number of confirmed attacks during a treatment period divided by the duration of the treatment (in days) times 7 days.
Time frame: 12 weeks
Number of Attack-free Days
The number of attack free days was the sum of the days during the treatment period for which participants reported no attacks.
Time frame: 12 weeks
Number of Participants Who Are Attack-free
The number of participants who reported no attacks during the 12-week treatment period.
Time frame: 12 weeks
Disease Activity, as Measured by the 84-day Angioedema Activity Score
Angioedema Activity Score (AAS) consists of 5 questions (period in which swelling occurred, physical discomfort, daily activity restriction, cosmetic disfigurement, and overall severity) to be answered for each day during which a subject experiences an HAE attack. A score between 0 (no symptoms) and 3 (Severe symptoms) was assigned to the responses for each question and the total daily score will be derived as the sum of the 5 question scores for each day during which the subject experiences a confirmed attack. Daily AAS ranged from 0 to 15 with higher scores indicating the greater disease severity. For participants who completed the study, the 84-day AAS was obtained by sum of AAS score during the treatment period and ranged from 0 (best) to 1,260 (worst).For participants who discontinued the study prematurely the 84-day AAS was obtained using the formula: Sum of AAS score of each day on treatment ∗ 84/Number of days on treatment.
Time frame: 12 weeks
Change From Baseline at Week 12, in Quality of Life as Measured by the Angioedema Quality of Life Questionnaire
Angioedema Quality of Life questionnaire (AE-QoL) consisted of 4 domains (i.e., functioning, fatigue/mood, fear/shame, and nutrition) and a total score based on a total of 17 possible responses. The results of all the responses are summed up and transformed to a scale ranging from 0 (best) to 100 (worst).
Time frame: Baseline (Day 1) and Week 12
Number of Participants With Treatment Emergent Adverse Events
An adverse event (AE) is any untoward medical occurrence in a clinical study participant. No causal relationship with study drug or with the clinical study itself is implied. An AE could be an unfavorable and unintended sign, symptom (including an abnormal laboratory finding), syndrome, or illness that developed or worsened during the clinical study. A serious adverse event (SAE) is any untoward medical occurrence resulting in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or other medically important event. Any graded abnormality that occurred following the initiation of study drug and up to 30 days after the last dose of study drug, and represented at least a 1-grade increase from the baseline assessment, was defined as treatment emergent.
Time frame: From first dose up to 14 weeks
Change From Baseline at Week 12 in Quality of Life, as Measured by the EuroQoL Five-dimensional, 5-level Questionnaire
The EuroQoL five-dimensional, 5-level (EQ-5D-5L) was used to assess overall wellbeing and comprised the following five domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 5 response levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. It included the EQ Visual Analogue scale (EQ VAS) to rate overall health on a scale of 0 (worst health) to 100 (best health).
Time frame: Baseline (Day 1) and Week 12
Participants were recruited from study sites in Belgium, Canada, France, Germany, Hungary, Italy, the United Kingdom and the United States, between December 2014 and October 2015
| Milestone | BCX4161 300 mg three times daily | BCX4161 500 mg three times daily | Placebo three times daily |
|---|---|---|---|
| Started | 36 | 38 | 36 |
| Completed | 35 | 35 | 33 |
| Not completed | 1 | 3 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Subject non-compliance | 0 | 0 | 1 |
An angioedema attack was defined as swelling at any location reported by participant, which had no swelling earlier. Total number of confirmed attacks during the treatment period standardized to a weekly attack-rate to adjust for the total duration of treatment. The attack rate was derived for each participant by treatment period. The weekly attack rate was equal to the total number of confirmed attacks during a treatment period divided by the duration of the treatment (in days) times 7 days.
| Confirmed attacks per week | BCX4161 300 mg three times daily | BCX4161 500 mg three times daily | Placebo three times daily |
|---|---|---|---|
| The Mean Acute Angioedema Attack Rate | 0.675 ± 0.089 | 0.589 ± 0.086 | 0.593 ± 0.088 |
The number of attack free days was the sum of the days during the treatment period for which participants reported no attacks.
| Number of attack-free days | BCX4161 300 mg three times daily | BCX4161 500 mg three times daily | Placebo three times daily |
|---|---|---|---|
| Number of Attack-free Days | 62.8 ± 18.2 | 66.0 ± 17.9 | 63.6 ± 14.9 |
The number of participants who reported no attacks during the 12-week treatment period.
| Participants | BCX4161 300 mg three times daily | BCX4161 500 mg three times daily | Placebo three times daily |
|---|---|---|---|
| Number of Participants Who Are Attack-free | 1 | 1 | 0 |
Angioedema Activity Score (AAS) consists of 5 questions (period in which swelling occurred, physical discomfort, daily activity restriction, cosmetic disfigurement, and overall severity) to be answered for each day during which a subject experiences an HAE attack. A score between 0 (no symptoms) and 3 (Severe symptoms) was assigned to the responses for each question and the total daily score will be derived as the sum of the 5 question scores for each day during which the subject experiences a confirmed attack. Daily AAS ranged from 0 to 15 with higher scores indicating the greater disease severity. For participants who completed the study, the 84-day AAS was obtained by sum of AAS score during the treatment period and ranged from 0 (best) to 1,260 (worst).For participants who discontinued the study prematurely the 84-day AAS was obtained using the formula: Sum of AAS score of each day on treatment ∗ 84/Number of days on treatment.
| score on a scale | BCX4161 300 mg three times daily | BCX4161 500 mg three times daily | Placebo three times daily |
|---|---|---|---|
| Disease Activity, as Measured by the 84-day Angioedema Activity Score | 113.9 ± 101.9 | 88.5 ± 85.1 | 97.2 ± 77.3 |
Angioedema Quality of Life questionnaire (AE-QoL) consisted of 4 domains (i.e., functioning, fatigue/mood, fear/shame, and nutrition) and a total score based on a total of 17 possible responses. The results of all the responses are summed up and transformed to a scale ranging from 0 (best) to 100 (worst).
| score on a scale | BCX4161 300 mg three times daily | BCX4161 500 mg three times daily | Placebo three times daily |
|---|---|---|---|
| Change From Baseline at Week 12, in Quality of Life as Measured by the Angioedema Quality of Life Questionnaire | -9.89 ± 3.11 | -17.45 ± 2.66 | -12.14 ± 2.64 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant. No causal relationship with study drug or with the clinical study itself is implied. An AE could be an unfavorable and unintended sign, symptom (including an abnormal laboratory finding), syndrome, or illness that developed or worsened during the clinical study. A serious adverse event (SAE) is any untoward medical occurrence resulting in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or other medically important event. Any graded abnormality that occurred following the initiation of study drug and up to 30 days after the last dose of study drug, and represented at least a 1-grade increase from the baseline assessment, was defined as treatment emergent.
| Participants | BCX4161 300 mg three times daily | BCX4161 500 mg three times daily | Placebo three times daily |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events | 31 | 35 | 32 |
The EuroQoL five-dimensional, 5-level (EQ-5D-5L) was used to assess overall wellbeing and comprised the following five domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 5 response levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. It included the EQ Visual Analogue scale (EQ VAS) to rate overall health on a scale of 0 (worst health) to 100 (best health).
| score on a scale | BCX4161 300 mg three times daily | BCX4161 500 mg three times daily | Placebo three times daily |
|---|---|---|---|
| Change From Baseline at Week 12 in Quality of Life, as Measured by the EuroQoL Five-dimensional, 5-level Questionnaire | 3.26 ± 2.38 | 2.41 ± 3.13 | 9.92 ± 1.72 |
Collected over From first dose up to 14 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BCX4161 300 mg three times daily | 0/36 (0%) | 2/36 (5.6%) | 31/36 (86.1%) |
| BCX4161 500 mg three times daily | 0/38 (0%) | 3/38 (7.9%) | 35/38 (92.1%) |
| Placebo three times daily | 0/36 (0%) | 3/36 (8.3%) | 32/36 (88.9%) |
| Event | BCX4161 300 mg three times daily | BCX4161 500 mg three times daily | Placebo three times daily |
|---|---|---|---|
| Hereditary angioedemaCongenital, familial and genetic disorders | 2/36 | 1/38 | 1/36 |
| Back painMusculoskeletal and connective tissue disorders | 0/36 | 0/38 | 1/36 |
| MigraineNervous system disorders | 1/36 | 0/38 | 0/36 |
| Abortion inducedSurgical and medical procedures | 0/36 | 0/38 | 1/36 |
| Chest discomfortGeneral disorders | 0/36 | 1/38 | 0/36 |
| Chest painGeneral disorders | 0/36 | 1/38 | 0/36 |
| Event | BCX4161 300 mg three times daily | BCX4161 500 mg three times daily | Placebo three times daily |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/36 | 16/38 | 12/36 |
| FlatulenceGastrointestinal disorders | 5/36 | 10/38 | 9/36 |
| NasopharyngitisInfections and infestations | 5/36 | 8/38 | 7/36 |
| HeadacheNervous system disorders | 4/36 | 7/38 | 6/36 |
| NauseaGastrointestinal disorders | 4/36 | 3/38 | 3/36 |
| Abdominal painGastrointestinal disorders | 3/36 | 4/38 | 2/36 |
| Abdominal distensionGastrointestinal disorders | 3/36 | 2/38 | 2/36 |
| Faeces softGastrointestinal disorders | 1/36 | 1/38 | 3/36 |
| SinusitisInfections and infestations | 1/36 | 1/38 | 3/36 |
| Blood alkaline phosphatase increasedInvestigations | 3/36 | 0/38 | 0/36 |
| Age, Continuous(years) | BCX4161 300 mg Three Times Daily | BCX4161 500 mg Three Times Daily | Placebo Three Times Daily | Total |
|---|---|---|---|---|
| Mean | 40.4 ± 12.4 | 41.1 ± 15.1 | 42.1 ± 12.5 | 41.2 ± 13.3 |
| Sex: Female, Male(Participants) | BCX4161 300 mg Three Times Daily | BCX4161 500 mg Three Times Daily | Placebo Three Times Daily | Total |
|---|---|---|---|---|
| Female | 29 | 30 | 26 | 85 |
| Male | 7 | 8 | 10 | 25 |
| Race (NIH/OMB)(Participants) | BCX4161 300 mg Three Times Daily | BCX4161 500 mg Three Times Daily | Placebo Three Times Daily | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 32 | 36 | 34 | 102 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 1 | 3 |
| Region of Enrollment(Participants) | BCX4161 300 mg Three Times Daily | BCX4161 500 mg Three Times Daily | Placebo Three Times Daily | Total |
|---|---|---|---|---|
| Canada | 3 | 1 | 1 | 5 |
| Hungary | 1 | 1 | 4 | 6 |
| Belgium | 0 | 1 | 1 | 2 |
| United States | 19 | 19 | 17 | 55 |
| Italy | 1 | 4 | 0 | 5 |
| United Kingdom | 6 | 5 | 3 | 14 |
| France | 3 | 1 | 2 | 6 |
| Germany | 3 | 6 | 8 | 17 |
| Qualifying attack rate(Attacks/ week) | BCX4161 300 mg Three Times Daily | BCX4161 500 mg Three Times Daily | Placebo Three Times Daily | Total |
|---|---|---|---|---|
| Mean | 0.93 ± 0.39 | 0.95 ± 0.39 | 0.92 ± 0.34 | 0.93 ± 0.37 |
Ran from Dec 2014 to primary completion in Jan 2016, 13 months.
Results were first posted in Nov 2025, 9 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avoralstat